Market reactionShares fell 11% on Nov 5.
Cabaletta Bio is a clinical-stage company developing rese-cel, a CD19-targeted CAR T-cell therapy for autoimmune diseases such as myositis, lupus and scleroderma; it is not approved.
Cabaletta's case rests on rese-cel, a one-time infusion of the patient's own T cells engineered against CD19 to reset the immune system in autoimmune disease. A BLA in the second half of 2027 depends on a 17-patient, single-arm myositis cohort with data in mid-2027; 8 of 10 earlier patients would have met its endpoint. Cash was $225.1 million at June 30 and warrant exercises added about $115.0 million, but Cabaletta has not updated its mid-2027 runway estimate.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Registrational RESET-Myositis cohort meets its endpoint
Do most of the 17 registrational patients reach a moderate or major TIS response off all immunomodulators?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cabaletta expects registrational RESET-Myositis data for rese-cel in mid-2027 to support a BLA in the second half of 2027; warrant exercises added about $115 million after June
Rese-cel's registrational myositis readout will test whether Phase 1/2 response rates hold in a confirmatory single-arm cohort supporting BLA submission
Equity offering of $150M at $2.90/share
RMAT designation granted for rese-cel in myositis
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Kidney diseases, Neuromuscular diseases, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
20 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.